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revision Clinical Modification. We con­
sidered the years before and after 2006 
as “before” or “after” vaccine introduc­
tion. Data on HPV vaccine coverage, 
estimated by the National Institutes of 
Health based on the vaccination in the 
age group 13–17 years, were retrieved 
from the Centers for Disease Control 
Web site.11
We included both sexes because, 
from the beginning of 2011, the Advi­
sory Committee on Immunization Prac­
tices has recommended the routine use 
of the quadrivalent (HPV) vaccine in 
young men and young women. We ana­
lyzed data on the rates of disease and 
vaccination considering the variation 
between calendar years in women of 
all ages and patients of both sexes 17 
years of age and younger because these 
groups were most likely to be exposed to 
the HPV vaccine.
As shown in Figure A, there was 
no increase in hospitalizations after the 
introduction of the HPV vaccine, con­
sidering women of all ages. Similarly, 
there was no increase when we consid­
ered only patients 17 years of age and 
younger from the National Inpatient 
Sample and the Kids’ Inpatient Sample 
(Figure B).
We carried out a further analysis 
of data from the Nationwide Emergency 
Department Sample for people admit­
ted to the emergency department with 
systemic lupus erythematosus as their 
first diagnosis. There was an increase in 
the number of emergency department 
admissions for women (Figure A). How­
ever, this appeared to apply only to older 
patients because it was not reproduced 
among those younger than 17 years 
( Figure B).
We could not obtain a reliable 
estimate of lupus hospitalization from 
the National Hospital Discharge Survey 
database because of the small number of 
patients who possibly had received the 
HPV vaccine. We found no evidence of 
an increase in the number of hospitaliza­
tions or emergency department admis­
sions because of lupus in patient groups 
exposed to HPV vaccine. This is consis­
tent with results from studies of patients 
receiving the HPV vaccine4 and with 
recently published guidelines from the 
European League Against Rheumatism.3
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Obese persons (those with a body mass index [BMI] ≥30 kg/m2) tend 
to underestimate their weight, leading to 
an underestimation of their true (mea­
sured) BMI and obesity prevalence.1,2 
In contrast, underweight people (BMI 
<18.5 kg/m2) tend to report themselves 
heavier, resulting in a higher BMI com­
pared with measured BMI and an under­
estimation of underweight prevalence.1
Less is known about biases in the 
estimate of mortality risk associated 
with these body weight categories using 
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self­reported data. It has been shown that 
the mortality risk of obesity based on self­
report can be overestimated, ie, biased 
away from the null.3,4 Underweight is asso­
ciated with an increased mortality risk5 
and, because underweight persons tend to 
overestimate BMI, one might intuitively 
expect that the mortality risk of under­
weight based on self­reported BMI would 
be underestimated, ie, biased toward the 
null (the opposite of the effect in obese 
persons). Is that a misleading intuition?
Consider a cohort of 1000 men, of 
whom 10% were underweight at baseline, 
70% had normal weight or were overweight, 
and 20% were obese, based on measured 
BMI. After 5 years, 36 men died (Table). 
The relative risk (RR) of death was higher 
in underweight (RR = 2.0) and obese men 
(RR = 1.5) compared with that in normal 
weight and overweight men combined. We 
assumed that the mortality risk was higher 
in the lowest (<17.5 kg/m2) category among 
underweight persons and in the highest BMI 
category (≥31 kg/m2) among obese persons.
Participants also reported their 
weight and height at baseline to com­
pute self­reported BMI. We assume 
that underweight men (measured BMI 
<18.5 kg/m2) overestimated their BMI by 
1  unit, on average. Consequently, men 
with measured BMI 17.5–18.4 kg/m2 
were classified as “normal weight” 
based on self­reported BMI, while in 
truth they were underweight (eAp­
pendix, eFigure, http://links.lww.com/
EDE/A735). Thus, using self­reported 
data, the prevalence of underweight was 
underestimated. Men with self­reported 
BMI <18.5 kg/m2 had a measured BMI 
<17.5 kg/m2. Therefore, these men had 
a higher mortality compared with men 
with true BMI <18.5 kg/m2 (8% vs. 6%).
We assume that obese men under­
estimated their BMI by 1  unit, on aver­
age. Therefore, men with true BMI 
30.0–31.0 kg/m2 were classified as normal 
weight/overweight based on self­reported 
BMI although they were in truth obese. 
Using self­reported data, the prevalence 
of obesity was underestimated. Men with 
self­reported BMI ≥30.0 kg/m2 had a mea­
sured BMI ≥31.0 kg/m2. Accordingly, they 
had a higher mortality compared with men 
with true BMI ≥30.0 kg/m2 (6% vs. 4.5%).
Using self­reported BMI to define 
body weight categories, the risk of under­
weight relative to normal/overweight was 
(4/50)/[(2 + 21 + 3)/(50 + 700 + 100)] = 
2.6, which was higher than the RR (2.0) 
obtained with measured BMI. The RR of 
obesity was (6/100)/[(2 + 21 + 3)/(50 + 700 
+ 100)] = 2.0, which was also higher than 
the RR (1.5) obtained with measured BMI.
Although self­reports lead to an 
overestimation of BMI by underweight 
persons and an underestimation by obese 
persons,1 the mortality (or disease) risk 
in both obese and underweight persons is 
likely overestimated when self­reported 
data are used to categorize people.
Our assumptions are simplistic. 
The errors in weight estimations depend 
on sex, age, and other characteristics,2,6 
and the direction of the bias will depend 
on how people in the various catego­
ries estimate their weight. The possible 
effects of exposure misclassification on 
the estimation of RR are complex and 
barely generalizable.7 Still, as shown, 
the effects of such misclassification 
can be counterintuitive. Direction and 
magnitude of bias should be evaluated 
carefully for each situation.7 The over­
estimation of obesity risk based on self­
reports has been demonstrated3,4 and 
recently corroborated in a meta­analy­
sis.8 Research is needed to confirm the 
bias entailed by defining underweight 
with self­reported data.
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TABLE. Hypothetical Cohort with 1000 Men Providing Measured and Self-
Reported Weight and Height to Compute Body Mass Index (BMI)
BMI Category 
and Measured 
BMI (kg/m2)
No.  
Men
No.  
Deaths
Body Weight 
Categories Based 
on Measured  
Data
Body Weight 
Categories Based 
on Self-Reported 
Data
Mortality 
Risk (%) RR
Mortality 
Risk (%) RR
Underweight
 <18.5 100 6 6.0 2.0
  <17.5 50 4 8.0 8.0 2.6
  17.5 to <18.4 50 2 4.0
Normal weight/overweighta
 18.5 to <29.9 700 21 3.0 1.0 3.1 1.0
Obese
 ≥30 200 9 4.5 1.5
  ≥30 to <30.9 100 3 3.0
  ≥31.0 100 6 6.0 6.0 2.0
aReference category.
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between this and the NNT: for the NNT 
“good” values are small values because 
only a small number of patients needs to 
be treated for one life to be saved or one 
failure to be avoided. In contrast, with 
the NAD, large values are better—we 
can expect a large number of patients to 
benefit from a correct diagnosis before a 
misdiagnosis occurs. With a prevalence 
of p, the NAD (earlier NNM) is given by
NAD=
1
Pr(misclassification)
=
1
1 se + 1­sp 1
.
− −( ) ( )( )p p
In the case of a population­based 
accuracy study that enables the estimation 
of both prevalence and accuracy, we can 
rewrite the number allowed to diagnose as
NAD=
1
FN+FP
TP+FN+FP+TN
=
1
1
TP+TN
TP+FN+FP+TN
=
1
1 Accuracy
,
−
−
with TP, FN, FP, and TN indicating 
the true positive, false negative, false 
positive, and true negative test results, 
respectively. Habibzadeh has pointed 
out a limitation of the number needed to 
misdiagnose, in that it treats the false­
positive and false­negative test results 
equally despite their quite different 
consequences for the patient. In many 
applications, however, this assumption 
of equal importance is not reasonable. 
An alternative weighting can be intro­
duced by assigning the costs c0 and c1 
to the false­positive and false­negative 
test results, respectively. Then the num­
ber allowed to diagnose can be general­
ized to the number of subjects needed to 
be diagnosed before we can expect the 
overall misclassification cost to equal 
the cost of misclassifying one randomly 
selected patient. The latter is equal to 
c1×p+c0×(1−p), and the expected misclas­
sification cost in N subjects is equal to
N c p c p1 01 1 1× −( ) + × − −( ) ( ) ( )( ) .se sp
When requiring these numbers to 
be equal or, alternatively, requiring their 
ratio to equal one, multiplication by N 
gives a cost­weighted version of the NAD:
NAD
se spcost
=
× + ×
× ( ) + × ( )( )
c p c p
c p c p
1 0
1 0
1
1 1 1
( )
.
−
− − −
It should be noted that the NAD­
cost depends only on the cost through 
the ratio c1/c0 (which can be easily seen 
by dividing both the numerator and the 
denominator by c0). Even when not 
thinking in terms of cost, but requiring 
sensitivity to be x times more important 
than specificity, we can choose c1 = x 
and c0 = 1. It is also possible to choose 
c1 and c0 so that they sum to 1.
4,5 Values 
for the NADcost vary considerably when 
cost ratios c1/c0 other than 1 are inves­
tigated (Table). Finally, assuming equal 
cost (c = c1 = c0), the NADcost simplifies 
to the NAD.
In summary, we recommend using 
the term “number allowed to diagnose” 
instead of “number needed to mis­
diagnose.” Furthermore, we suggest 
including weights for sensitivity and 
specificity in the computations if there 
TABLE.  NADcost Values for se = 0.9,  
sp = 0.6, and Various Values for the 
Prevalence p and Cost Ratio c1/c0
Prevalence p
Cost Ratio c1/c0
10 3 1 0.3 0.1
0.01 2.7 2.6 2.5 2.5 2.5
0.05 3.4 2.8 2.6 2.5 2.5
0.1 4.1 3.1 2.7a 2.6 2.5
0.2 5.4 3.7 2.9 2.6 2.5
0.5 7.9 5.7 4.0 3.0 2.7
0.8 9.3 8.1 6.3 4.2 3.2
0.9 9.7 9.0 7.7 5.5 3.9
0.95 9.8 9.5 8.7 6.9 4.9
0.99 10.0 9.9 9.7 9.1 7.8
aValue corresponding to the value in Habibzadeh’s 
example.3
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Number Allowed to 
Diagnose
To the Editor:
In diagnostic research, diagnostic procedures must be able to discrimi­
nate between diseased and disease­free 
patients. Such discrimination is usually 
expressed as a combination of sensitiv­
ity (se) and specificity (sp). Having two 
criteria makes it more cumbersome to 
compare diagnostic modalities than 
therapeutic regimes, which can be sum­
marized by a single endpoint such as 
overall survival. Analogous to the num­
ber needed to treat (NNT) in treatment 
trials,1 the number needed to diagnose2 
has been proposed as a single summary 
statistic for diagnostic tests. However, as 
pointed out by Habibzadeh,3 the number 
needed to diagnose lacks clinical utility. 
Moreover, it seeks to construct an anal­
ogy to treatment trials—an analogy that, 
in our view, just does not exist.
Turning to a variant that is both 
clinically interpretable and useful, 
Habibzadeh3 has introduced the number 
needed to misdiagnose (NNM), which 
gives the number of persons needed to be 
diagnosed before one misclassified per­
son can be expected. We suggest chang­
ing the name of this number to the number 
allowed to diagnose (NAD) because this 
would reflect the fundamental difference 
Copyright © 2013 by Lippincott Williams & Wilkins
ISSN: 1044­3983/14/2501­0158
DOI: 10.1097/EDE.0b013e3182a77a81
The authors have no conflicts of interest to declare.
